Schedule 13G Filing by Millennium Management Entities for BioXcel Therapeutics

Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly filed a Schedule 13G with the SEC, disclosing their beneficial ownership of 5.2% of the common stock of BioXcel Therapeutics, Inc. The filing, made under Rule 13d-1(c), indicates that the shares are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers controlled by Millennium Group Management LLC and Israel A. Englander. The filing includes a Joint Filing Agreement dated September 30, 2025, confirming the joint filing on behalf of all entities and individuals involved.